Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Kodiak Sciences price target lowered to $90 from $101 at SunTrust » 09:28
05/14/20
05/14
09:28
05/14/20
09:28
KOD

Kodiak Sciences

$53.89 /

-1.94 (-3.47%)

SunTrust analyst Robyn…

SunTrust analyst Robyn Karnauskas lowered the firm's price target on Kodiak Sciences to $90 from $101 but keeps a Buy rating on the shares. The company's pivotal study initiations were pushed out one quarter from June/July to Sept/Oct 2020 to minimize impact from COVID-19 on clinical trial conduct, but its 2022 goal towards BLA filing in key retinal diseases remains intact, the analyst tells investors in a research note.

ShowHide Related Items >><<
KOD Kodiak Sciences
$53.89 /

-1.94 (-3.47%)

KOD Kodiak Sciences
$53.89 /

-1.94 (-3.47%)

03/31/20 BMO Capital
Kodiak Sciences initiated with an Outperform at BMO Capital
03/02/20 Goldman Sachs
Kodiak Sciences initiated with a Buy at Goldman Sachs
02/18/20 Barclays
Kodiak Sciences downgraded to Equal Weight from Overweight at Barclays
02/18/20 Barclays
Kodiak Sciences downgraded to Equal Weight from Overweight at Barclays
KOD Kodiak Sciences
$53.89 /

-1.94 (-3.47%)

KOD Kodiak Sciences
$53.89 /

-1.94 (-3.47%)

KOD Kodiak Sciences
$53.89 /

-1.94 (-3.47%)

Earnings
Kodiak Sciences reports Q1 EPS (54c), consensus (46c) » 05:58
05/11/20
05/11
05:58
05/11/20
05:58
KOD

Kodiak Sciences

$57.18 /

+1.81 (+3.27%)

"I am proud of the…

"I am proud of the dedication and passion of our people who continue to deliver on our mission to help patients with serious retinal diseases as we all navigate the challenges of the COVID-19 pandemic," said Victor Perlroth, MD, chairman and CEO of Kodiak Sciences. "To date, we are seeing minimal disruption from COVID-19 in our ongoing clinical trials. In DAZZLE, patient missed visit rates are less than 5%, and clinical trial sites continue to enroll new patients. This is a testament to the serious diseases we are attempting to treat and is a vote of confidence from the patients, physicians and study sites partnering with us to advance KSI-301. With over $430 million in cash, cash equivalents and marketable securities at quarter end, and thoughtful management of our spending, we remain on a strong financial footing. We did delay initiation of our next set of KSI-301 pivotal studies by one quarter from June/July to September/October 2020 in order to assess with physicians and our business partners how best to minimize the impact of COVID-19 on clinical trial conduct. But our 2022 Vision towards a BLA filing in the key retinal disease indications remains intact, and we have taken good advantage of this additional time to upgrade our pivotal study plan for KSI-301. We now intend to conduct two phase 3 studies in DME, one study in wet AMD (our ongoing DAZZLE study), one study in RVO, and one study in non-proliferative DR. There are multiple reasons for this shift into two DME studies (and one RVO study) from our earlier plan of two RVO studies (and one DME study). Operationally, we expect faster, simpler and more predictable enrollment in the DME indication and will be able to run the studies in fewer countries and research sites. And further, we prefer to shift resources on the margin into this higher prevalence, higher unmet need disease which remains the leading cause of blindness in working-aged adults in the United States and the EU. Importantly, the data emerging in our phase 1b study remain consistent with our observations shared in February, and we look forward to providing another R&D update in July of this year, either virtually or at the American Society of Retina Specialists meeting. We also recognize the critical role the biopharma industry plays in fighting COVID-19 by developing effective therapies, and we have therefore taken action to explore whether our anti-IL-6/anti-VEGF bispecific protein that is a component of KSI-501 may be an effective therapeutic strategy in patients with severe COVID-19.

ShowHide Related Items >><<
KOD Kodiak Sciences
$57.18 /

+1.81 (+3.27%)

03/31/20 BMO Capital
Kodiak Sciences initiated with an Outperform at BMO Capital
03/02/20 Goldman Sachs
Kodiak Sciences initiated with a Buy at Goldman Sachs
02/18/20 Barclays
Kodiak Sciences downgraded to Equal Weight from Overweight at Barclays
02/18/20 Barclays
Kodiak Sciences downgraded to Equal Weight from Overweight at Barclays
Conference/Events
Kodiak Sciences participates in a conference call with JPMorgan » 11:25
05/04/20
05/04
11:25
05/04/20
11:25
KOD

Kodiak Sciences

$50.88 /

+0.02 (+0.04%)

Biotech Analyst Rama…

Biotech Analyst Rama holds a conference call with CEO Perlroth on May 4 at 12 pm hosted by JPMorgan.

ShowHide Related Items >><<
KOD Kodiak Sciences
$50.88 /

+0.02 (+0.04%)

03/31/20 BMO Capital
Kodiak Sciences initiated with an Outperform at BMO Capital
03/02/20 Goldman Sachs
Kodiak Sciences initiated with a Buy at Goldman Sachs
02/18/20 Barclays
Kodiak Sciences downgraded to Equal Weight from Overweight at Barclays
02/18/20 Barclays
Kodiak Sciences downgraded to Equal Weight from Overweight at Barclays
Conference/Events
Kodiak Sciences participates in a conference call with JPMorgan » 04:55
05/04/20
05/04
04:55
05/04/20
04:55
KOD

Kodiak Sciences

$50.86 /

-3.61 (-6.63%)

Biotech Analyst Rama…

Biotech Analyst Rama holds a conference call with CEO Perlroth on May 4 at 12 pm hosted by JPMorgan.

ShowHide Related Items >><<
KOD Kodiak Sciences
$50.86 /

-3.61 (-6.63%)

03/31/20 BMO Capital
Kodiak Sciences initiated with an Outperform at BMO Capital
03/02/20 Goldman Sachs
Kodiak Sciences initiated with a Buy at Goldman Sachs
02/18/20 Barclays
Kodiak Sciences downgraded to Equal Weight from Overweight at Barclays
02/18/20 Barclays
Kodiak Sciences downgraded to Equal Weight from Overweight at Barclays
Over a month ago
Conference/Events
Kodiak Sciences participates in a conference call with JPMorgan » 09:58
05/01/20
05/01
09:58
05/01/20
09:58
KOD

Kodiak Sciences

$52.05 /

-2.42 (-4.44%)

Biotech Analyst Rama…

Biotech Analyst Rama holds a conference call with CEO Perlroth on May 4 at 12 pm hosted by JPMorgan.

ShowHide Related Items >><<
KOD Kodiak Sciences
$52.05 /

-2.42 (-4.44%)

03/31/20 BMO Capital
Kodiak Sciences initiated with an Outperform at BMO Capital
03/02/20 Goldman Sachs
Kodiak Sciences initiated with a Buy at Goldman Sachs
02/18/20 Barclays
Kodiak Sciences downgraded to Equal Weight from Overweight at Barclays
02/18/20 Barclays
Kodiak Sciences downgraded to Equal Weight from Overweight at Barclays
Initiation
Kodiak Sciences initiated with an Outperform at BMO Capital » 05:05
03/31/20
03/31
05:05
03/31/20
05:05
KOD

Kodiak Sciences

$50.08 /

+2.29 (+4.79%)

BMO Capital analyst…

BMO Capital analyst Matthew Luchini initiated coverage of Kodiak Sciences with an Outperform rating and $74 price target. The company's lead drug, KSI-301, has the potential to disrupt the multi-billion dollar anti-VEGF market, Luchini tells investors in a research note. The analyst believes KSI-301's Phase 1b data provides "encouraging" proof-of-concept, showing promising efficacy and clean safety plus potential to meaningfully extend the dosing interval versus existing anti-VEGFs.

ShowHide Related Items >><<
KOD Kodiak Sciences
$50.08 /

+2.29 (+4.79%)

03/02/20 Goldman Sachs
Kodiak Sciences initiated with a Buy at Goldman Sachs
02/18/20 Barclays
Kodiak Sciences downgraded to Equal Weight from Overweight at Barclays
02/18/20 Barclays
Kodiak Sciences downgraded to Equal Weight from Overweight at Barclays
02/10/20 Roth Capital
Kodiak Sciences study data align with bullish expectations, says Roth Capital
Hot Stocks
Kodiak Sciences receives full registration of its trademarks » 08:52
03/24/20
03/24
08:52
03/24/20
08:52
KOD

Kodiak Sciences

$46.44 /

+1.5 (+3.34%)

Kodiak Sciences announced…

Kodiak Sciences announced that the company received full registration of their trademarks "Kodiak" and "Kodiak Sciences" from the U.S. Patent and Trademark Office for the exclusive use of Kodiak Sciences and its subsidiaries.

ShowHide Related Items >><<
KOD Kodiak Sciences
$46.44 /

+1.5 (+3.34%)

03/02/20 Goldman Sachs
Kodiak Sciences initiated with a Buy at Goldman Sachs
02/18/20 Barclays
Kodiak Sciences downgraded to Equal Weight from Overweight at Barclays
02/18/20 Barclays
Kodiak Sciences downgraded to Equal Weight from Overweight at Barclays
02/10/20 Roth Capital
Kodiak Sciences study data align with bullish expectations, says Roth Capital
Earnings
Kodiak Sciences reports Q4 EPS (40c), consensus (35c) » 05:48
03/16/20
03/16
05:48
03/16/20
05:48
KOD

Kodiak Sciences

$53.25 /

+3.435 (+6.90%)

"We made tremendous…

"We made tremendous progress this past year toward our goal of developing a next generation platform for retinal medicines," said Victor Perlroth, MD, CEO of Kodiak Sciences. "We remain very pleased with the emerging clinical profile of KSI-301, our first product candidate built on our ABC Platform. We continue to see impressive safety, efficacy and durability data across our active clinical studies. We initiated our first pivotal clinical study (DAZZLE) assessing KSI-301 in wet age-related macular degeneration (wet AMD) patients. We held a productive End-of-Phase 2 meeting with the FDA in which we reached agreement on an innovative clinical plan for registration. We secured substantive resources to fund accelerated clinical, manufacturing, and commercial plans for KSI-301. We look forward to initiating four more pivotal studies for KSI-301 later this year. We remain focused on achieving our 2022 Vision of filing a BLA in wet AMD, Diabetic Macular Edema, and Retinal Vein Occlusion, or RVO, in 2022."

ShowHide Related Items >><<
KOD Kodiak Sciences
$53.25 /

+3.435 (+6.90%)

03/02/20 Goldman Sachs
Kodiak Sciences initiated with a Buy at Goldman Sachs
02/18/20 Barclays
Kodiak Sciences downgraded to Equal Weight from Overweight at Barclays
02/18/20 Barclays
Kodiak Sciences downgraded to Equal Weight from Overweight at Barclays
02/10/20 Roth Capital
Kodiak Sciences study data align with bullish expectations, says Roth Capital
Over a quarter ago
Initiation
Kodiak Sciences initiated with a Buy at Goldman Sachs » 17:25
03/02/20
03/02
17:25
03/02/20
17:25
KOD

Kodiak Sciences

$67.71 /

+3.89 (+6.10%)

Goldman Sachs analyst…

Goldman Sachs analyst Graig Suvannavejh initiated coverage of Kodiak Sciences (KOD) with a Buy rating and $80 price target. The analyst sees KSI-301, the company's lead asset, as the "next potentially significant incremental advancement for eye diseases treated by anti-VEGF-based therapies." Suvannavejh added that despite many existing therapies, there is still a significant unmet market that KSI-301 "could easily address." Suvannavejh also noted that Kodiak has negotiated a novel clinical development program for KSI-301 with the FDA that will reduce timelines and accelerate time to revenue, and the analyst added that the company is "well-positioned from a funding perspective."

ShowHide Related Items >><<
KOD Kodiak Sciences
$67.71 /

+3.89 (+6.10%)

02/18/20 Barclays
Kodiak Sciences downgraded to Equal Weight from Overweight at Barclays
02/18/20 Barclays
Kodiak Sciences downgraded to Equal Weight from Overweight at Barclays
02/10/20 Roth Capital
Kodiak Sciences study data align with bullish expectations, says Roth Capital
02/05/20 SunTrust
Kodiak Sciences initiated with a Buy at SunTrust
Downgrade
Kodiak Sciences downgraded to Equal Weight from Overweight at Barclays » 07:34
02/18/20
02/18
07:34
02/18/20
07:34
KOD

Kodiak Sciences

$59.96 /

-2.77 (-4.42%)

Barclays analyst Gena…

Barclays analyst Gena Wang downgraded Kodiak Sciences to Equal Weight from Overweight with a price target of $69, up from $26. After the recent Angiogenesis update, the analyst does not see major upside from Phase 1b long-term data. As such, she sees a balanced risk/reward for the shares before Phase 3 trials read out starting on the second half of 2022. Her increased price target reflects enhanced conviction on KSI-301's clinical profile and market opportunity.

ShowHide Related Items >><<
KOD Kodiak Sciences
$59.96 /

-2.77 (-4.42%)

02/18/20 Barclays
Kodiak Sciences downgraded to Equal Weight from Overweight at Barclays
02/10/20 Roth Capital
Kodiak Sciences study data align with bullish expectations, says Roth Capital
02/05/20 SunTrust
Kodiak Sciences initiated with a Buy at SunTrust
01/08/20
Fly Intel: Top five analyst initiations

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.